Patents Assigned to Xoma Technology Ltd.
  • Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatment
    Patent number: 12071475
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: August 27, 2024
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Daniel H. Bedinger, Shireen S. Khan, Amer M. Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody
    Patent number: 11685775
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: June 27, 2023
    Assignees: XOMA TECHNOLOGY LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3
    Patent number: 11098111
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: August 24, 2021
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof
    Patent number: 11034759
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: June 15, 2021
    Assignees: Novartis Vaccines and Diagnostics, Inc., Xoma Technology Ltd.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Treatment of cancer using anti-TGF-? and anti-PD-1 antibodies
    Patent number: 10683347
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: June 16, 2020
    Assignees: XOMA Technology Ltd., The Regents of the University of California
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (TGF)-?
    Patent number: 10358486
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 23, 2019
    Assignee: XOMA Technology, Ltd.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
    Patent number: 10167334
    Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
    Type: Grant
    Filed: April 3, 2016
    Date of Patent: January 1, 2019
    Assignees: XOMA TECHNOLOGY LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Amer M. Mirza, Rosemary J. Akhurst, Ou Li
  • M-CSF specific monoclonal antibody and uses thereof
    Patent number: 9926371
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: March 27, 2018
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS, INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Screening methods
    Patent number: 9885711
    Abstract: The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: February 6, 2018
    Assignee: XOMA Technology Ltd.
    Inventors: Mark L. White, Marina Roell, John Corbin, Robert Bauer, Daniel Bedinger
  • Methods and materials for enhancing functional protein expression in bacteria
    Patent number: 9732143
    Abstract: Novel materials and methods useful for expressing heterologous proteins in prokaryotic cells are provided, including prokaryotic cells expressing FkpA and/or Skp.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: August 15, 2017
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Raphael D. Levy, Chung-Leung Chan, Kiranjit K. Ahluwalia, Toshihiko Takeuchi
  • TGF-beta-specific antibodies and methods of use thereof for treatment
    Patent number: 9714285
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 25, 2017
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20170152311
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: November 9, 2016
    Publication date: June 1, 2017
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Antagonist antibodies against EphB3
    Patent number: 9541004
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: January 10, 2017
    Assignees: NOVARTIS AG, XOMA TECHNOLOGY LTD.
    Inventors: Linda Masat, Jeff Hsu
  • M-CSF specific monoclonal antibody and uses therof
    Patent number: 9522186
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: December 20, 2016
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEROF
    Publication number: 20160015809
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: June 3, 2015
    Publication date: January 21, 2016
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • Antibody Coformulations
    Publication number: 20150308988
    Abstract: This invention relates to stable formulations of multiple antibodies comprising a plurality of antibodies and an effective amount of a succinate buffer wherein the pH of the formulation is between about 4.5 and about 7.0.
    Type: Application
    Filed: July 14, 2015
    Publication date: October 29, 2015
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: Susan Joyce Babuka, Chin-Yi Huang, Mingxiang Li
  • Antibodies specific for TGF-? and methods of treatment thereof
    Patent number: 9145458
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: September 29, 2015
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • Methods and materials for targeted mutagenesis
    Patent number: 9102711
    Abstract: The present disclosure relates to methods and materials for mutagenesis, including for the generation of novel or improved proteins and libraries or arrays of mutant proteins or nucleic acids encoding such mutant proteins.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: August 11, 2015
    Assignee: XOMA TECHNOLOGY LTD.
    Inventor: Toshihiko Takeuchi
  • Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins
    Patent number: 9096664
    Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: August 4, 2015
    Assignees: AVEO Pharmaceuticals, Inc., Xoma Technologies, Ltd.
    Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
  • M-CSF specific monoclonal antibody and uses thereof
    Patent number: 9079956
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 14, 2015
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz